Trius Therapeutics Inc (TSRX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access TSRX Annual Balance Sheets →
The table below presents a historical view of Trius Therapeutics Inc's balance sheet, supporting analysis of financial position trends.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2013)
(Mar 31 2013) (Dec 31 2012) (Sep 30 2012) (Jun 30 2012)
Assets
Cash & cash equivalent15.32
Restricted Cash and Cash Equivalents, Current0.15
Available-for-sale Securities, Current MA54.26
Cash & Short-term Investments69.00
Accounts receivable1.92
Prepaid Expense And Other Assets Current1.43
Total Current Assets73.07
Equipment/Property/Plant Net0.84
Long-term investments0.00
Other Assets, Noncurrent0.15
Total Assets74.06
Liabilities
Accounts Payable, Current AC5.42
Accrued Liabilities, Current AC7.36
Other Liabilities, Current0.00
Deferred Revenue, Current DE0.02
Total Current Liabilities19.38
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Common Stock Warrants Liability Current6.57
Total Liabilities19.38
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock240.95
Retained Earnings / Accumulated Deficit-186.28
Defined Benefit Plan and Other0.00
Other Equity0.01
Common Stockholder's Equity54.68
Total Stockholder's Equity54.68
Liabilities & Stockholder's Equity74.06
4 historic quarters locked

Sign in to unlock the full Trius Therapeutics Inc balance sheet history.

About TSRX Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.